Tazbentetol - Spinogenix
Alternative Names: SPG-302; Tazbentetol-SpinogenixLatest Information Update: 25 Dec 2025
At a glance
- Originator Spinogenix
- Class Antidementias; Antiglaucomas; Antineoplastics; Antipsychotics; Benzene derivatives; Benzothiazoles; Ethylene glycols; Neuroprotectants; Small molecules
- Mechanism of Action Synaptic transmission modulators
-
Orphan Drug Status
Yes - Amyotrophic lateral sclerosis
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Alzheimer's disease; Amyotrophic lateral sclerosis; Schizophrenia
- Preclinical Glaucoma
Most Recent Events
- 08 Dec 2025 Spinogenix completes phase II clinical trials in Alzheimer's disease in Australia (PO) (NCT06427668)
- 08 Dec 2025 Updated efficacy, adverse events and pharmacodynamics data from a phase II clinical trial in Alzheimer's disease
- 01 Dec 2025 The International Nonproprietary Names (INN) Expert Committee of the World Health Organization approves 'tazbentetol' as the non-proprietary name of SPG